Medigene AG

Medigene AG is a pioneering immuno-oncology platform company focused on developing innovative T-cell therapies designed to eradicate cancer effectively. Medigene AG's comprehensive technology platform is built upon a foundation of proprietary and exclusive product development technologies, enabling the creation of best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies. These therapies are specifically tailored for multiple solid tumor indications and optimized for both safety and efficacy.

Located at Lochhamer Strasse 11, Planegg, BY 82152, DE, Medigene AG is dedicated to advancing its in-house therapeutics pipeline and fostering strategic partnerships to expand the reach of its cutting-edge treatments. The company’s commitment to innovation and excellence positions it as a leader in the rapidly evolving field of immuno-oncology, driving progress in the fight against cancer.

Medigene AG invites you to explore the potential of its groundbreaking T-cell therapies and discover how its advancements are shaping the future of cancer treatment. We encourage the management team to create a customized and exclusive company showcase and product listing on our platform to further highlight Medigene AG's unique contributions and capabilities.